Canaccord analyst William Plovanic raised the firm’s price target on Edwards Lifesciences (EW) to $75 from $71. The firm said Edwards delivered ...

In a report released today, Matt Miksic from Barclays reiterated a Buy rating on Edwards Lifesciences (EW – Research Report), with a price ...

First quarter earnings reports from Edwards Lifesciences Corp., Intuitive Surgical Inc. and Boston Scientific Corp. support trends seen earlier: Larger med-tech companies expect substantial tariff ...

Shares of Edwards Lifesciences Corp. EW rose 6.63% to $75.13 Thursday, on what proved to be an all-around great trading ...

Edwards Lifesciences raised 2025 revenue forecast after Q1 results beat EPS estimates and TMTT sales jumped 58% amid strong ...

The heart valve specialist saw better-than-expected TAVR sales in the first quarter as hospitals addressed capacity ...

Fintel reports that on April 24, 2025, Piper Sandler upgraded their outlook for Edwards Lifesciences (NYSE:EW) from Neutral ...

Q1 2025 Management View CEO Bernard Zovighian outlined that total company sales grew 8% to $1.41 billion in Q1 2025, driven ...

Edwards Lifesciences Corporation ( NYSE: EW) Q1 2025 Earnings Conference Call April 23, 2025 5:00 PM ET Mark Wilterding - SVP, Global Finance Bernard Zovighian - CEO Scott Ullem - CFO Daveen Chopra - ...

Edwards Lifesciences (NYSE: EW) shares stayed put after hours today on first-quarter results that beat Wall Street ...

Edwards Lifesciences raised its 2025 sales forecast on Wednesday after a quarterly beat, driven by robust demand for its artificial heart valves and other medical equipment.